Objective: We aimed to quantify the risk and predictors of ipsilateral ischemic stroke in patients with symptomatic carotid stenosis awaiting revascularization (carotid endarterectomy [CEA] or carotid artery stenting) by pooling individual patient data from recent prospective studies with high rates of treatment with modern stroke prevention medications.
Pooled analysis of randomized clinical trials of carotid endarterectomy (CEA) for symptomatic carotid stenosis have demonstrated that maximal benefit is obtained when revascularization is performed within 2 weeks after randomization, leading to guidelines recommending early surgery. 1-3 However, the optimal timing of carotid revascularization within the first 2 weeks is unresolved, with 2 large studies (each including .2,500 operations) reporting an increased periprocedural risk of stroke and death in patients undergoing early CEA. 4, 5 Moreover, despite advances in stroke prevention therapeutics, the risk of early recurrent stroke in medically treated patients with carotid stenosis is also substantial. [6] [7] [8] [9] [10] We and others have reported high risk of ipsilateral recurrent stroke (between 4.0% and 17.2%) within 48-72 hours after symptom onset. [6] [7] [8] [9] [10] While providing valuable information, earlier studies have been limited by inclusion of patients ineligible for carotid revascularization and relatively small sample sizes, leading to imprecision and wide confidence intervals (CIs) around the point estimates of recurrent stroke risk, and insufficient statistical power for analysis of determinants of early stroke recurrence. To improve identification of patients at highest risk of early recurrent stroke who might benefit from urgent carotid revascularization, larger studies providing accurate estimates of early stroke risk in patients deemed eligible for CEA or carotid artery stenting (CAS) are needed.
We aimed to determine the risk and predictors of major preprocedural ipsilateral ischemic events (stroke and retinal artery occlusion [RAO]) among patients with symptomatic 50%-99% carotid stenosis eligible for CEA/ CAS by pooling individual patient data from 3 recent prospective studies with high rates of treatment with modern stroke prevention medications. METHODS We pooled individual patient data from prospective cohort studies from 3 European centers, each previously described. [6] [7] [8] Two centers (Umeå, Sweden; and Barcelona, Spain) provided data from prospective hospital-based registries serving local communities and regional hospitals. One center (Dublin, Ireland) provided data from a 2006 population-based study (including all unselected community-and hospital-based patients) and a later (2007-2011) prospective hospital-based study of blood and imaging biomarkers that included patients with TIA or minor stroke (modified Rankin Scale [mRS] score 0-2). Detailed center descriptions are presented in table e-1 on the Neurology ® Web site at Neurology.org.
Demographic and clinical parameters, medical treatments, time between presenting event and CEA/CAS, and early recurrent events were compared and pooled in a single database (table 1 and appendix e-1).
Inclusion criteria were as follows: (1) symptomatic 50%-99% carotid stenosis; (2) symptom onset (cerebral or retinal ischemic event) within 6 months of first health care contact; (3) patient deemed eligible for CEA/CAS in the opinion of the treating clinicians. Eligibility for CEA/CAS was defined as follows: (1) completion of CEA or CAS; (2) noncompletion of a planned CEA/CAS due to a disabling or fatal recurrent stroke while awaiting revascularization; (3) patient refusal to proceed with CEA/ CAS recommended by treating clinicians.
Exclusion criteria were as follows: (1) ineligibility for CEA/ CAS in the opinion of the treating clinician, for reasons such as low likelihood of benefit, high periprocedural risk or comorbidities, or technical difficulties; (2) as we aimed to analyze the risk of ischemic events prior to planned revascularization, patients with CEA/CAS performed within 24 hours of the presenting stroke/TIA were excluded (figure 1).
Definitions. The presenting event was defined as the last event before the patient first sought medical attention, classified as ischemic stroke (according to WHO definition, with hemorrhagic stroke or stroke mimic excluded by brain imaging), TIA (transient neurologic symptoms due to cerebral ischemia lasting less than 24 hours), RAO (retinal ischemic event lasting longer than 24 hours), or amaurosis fugax (retinal ischemic event lasting less than 24 hours). The traditional (time-based) definition of TIA was used to allow standardized comparisons across included studies.
Carotid stenosis was defined as 50%-99% lumen narrowing, using North American Symptomatic Carotid Endarterectomy Trial criteria applied by the reporting radiologist at each center, based on ultrasound, CT angiography, magnetic resonance angiography with either contrast or with time-of-flight sequences, or conventional angiography. 1, 11, 12 The primary endpoint was prespecified as an ipsilateral ischemic stroke or RAO to allow comparison with the endpoint used in pooled analysis of large randomized trials by the Carotid Endarterectomy Trialists Collaboration. 1 Secondary endpoints were (1) disabling or fatal ipsilateral ischemic stroke, (2) any ischemic stroke or retinal artery occlusion, and (3) any ipsilateral ischemic event (stroke, RAO, TIA, amaurosis fugax). For all endpoints, only ischemic events that occurred after the presenting event but before planned CEA/CAS were counted. Disabling/fatal ipsilateral ischemic stroke was defined as mRS 3-6 at follow-up, consistent with Carotid Endarterectomy Trialists Collaboration criteria. 13 In all 3 centers, patients with atrial fibrillation and ischemic stroke or TIA confined to the territory of an ipsilateral 50%-99% carotid stenosis were considered for revascularization.
Follow-up. Follow-up for outcome of stroke and ischemic events was performed at 1, 2, 3, 7, 14, 30, and 90 days after the presenting event. Data relating to recurrent stroke severity were ascertained at 90 days or at 1 year depending on center. Follow-up assessments were performed prospectively by inperson or telephone interview by trained study personnel and verified by stroke clinicians by in-person reviews supplemented by review of the medical files. Two patients (0.5%) presented to medical attention later than 90 days after their presenting event but within 6 months. For these patients, follow-up for recurrent stroke/RAO within 90 days within the presenting event was completed when they sought health care per our prespecified inclusion criteria, by retrospective review of medical files.
Statistical analysis. The risk of ipsilateral ischemic stroke recurrence after the presenting event was calculated using time-toevent survival analysis, with Kaplan-Meier curves and censoring for outcome events or CEA/CAS. Bivariate comparisons of the 90-day risk of the primary endpoint among subgroups were compared using the log-rank test.
To examine the relationship between clinically relevant covariates and preprocedural recurrent stroke, we performed backward stepwise multivariable Cox regression analysis, after first verifying adherence to the underlying assumptions required for Cox regression modeling (see appendix e-1). After first determining the unadjusted hazard ratio (HR) for all covariates, we then produced 2 models: (1) HRs for all covariates adjusted for age, sex, and study center; (2) HR adjusted for multiple covariates, where all 14 covariates were initially entered into the model and the variable with the highest p value was then removed in a stepwise fashion until all remaining parameters had a p value of ,0.10.
We used the 2-sided x 2 test for comparison of proportions. Nonparametric continuous variables are presented with median and interquartile range (IQR) and were analyzed with the Kruskal-Wallis test. A p value of ,0.05 was set as threshold for statistical significance. We used SPSS 22.0 statistical software.
Standard protocol approvals, registrations, and patient consents. The study was approved in each center by the local ethical committee.
RESULTS Clinical characteristics. A total of 607 patients with symptomatic carotid stenosis were ascertained in the 3 centers. Of these, 227 (37%) were ineligible for revascularization and 3 (0.5%) underwent CAS within 24 hours and were excluded. Reasons for ineligibility are described in figure 1. For 67 patients (11%), the reason for not proceeding with CEA/CAS could not be determined due to inadequate documentation. In total, 377 patients met our prespecified criteria and were included in the pooled analysis. Of these, 259 (69%) were men and the median age was 71 years (IQR 65-77). Clinical characteristics are described in tables 1, e-1, and appendix e-1.
Within 48 hours, 329 (91%) patients were treated with antithrombotic medication (200 [61%] antiplatelet monotherapy, 69 [21%] dual antiplatelet therapy, 60 [18%] anticoagulant therapy). Fewer patients in Umeå were treated with early statins (64% vs 77% vs 81%, p 5 0.001). Fifty-four percent of Dublin patients had revascularization within 14 days of symptom onset, compared with 24% (Umeå) and 16% (Barcelona) (p , 0.001). CAS was used more frequently in Dublin (20%) than Umeå (1%) or Barcelona (12%) (p , 0.001) (table e-2).
Recurrent stroke before CEA/CAS. Fifty-one patients had a recurrent ipsilateral ischemic stroke or RAO within 90 days of the presenting event. Across all 3 centers, the pooled risk of recurrent ipsilateral ischemic stroke or RAO was 2.7% at 1 day, 6.6% at 3 days, 11.5% at 14 days, and 18.8% at 90 days (figure 2 and table e-3). Recurrent stroke was the most frequent outcome event (47/51 patients, 92%). Disabling or fatal recurrent stroke occurred in 31% (16/51) of these, with fatal stroke in 6 patients (table e-3).
In addition to the 51 patients who had a recurrent ipsilateral ischemic stroke or RAO, 3 patients had contralateral ischemic stroke/RAO, all later than 14 days after the presenting event.
The risk of any ipsilateral ischemic recurrent event (stroke, RAO, TIA, or amaurosis fugax) was approximately double that of ipsilateral ischemic stroke/RAO at each time interval (table e-3). Data on atrial fibrillation status were available for 48/ 51 patients with recurrent stroke. Of these, 8/48 (16.7%) had atrial fibrillation. Data on early statin and antithrombotic prescribing were unavailable in 2 patients (table e-4). Factors associated with early recurrence. On bivariate Kaplan-Meier analysis, the risk of early recurrent ipsilateral ischemic stroke/RAO was increased for patients presenting with cerebral (stroke/TIA) compared with ocular (amaurosis/RAO) events (logrank p 5 0.04), and with early antiplatelet/ anticoagulant medication use (p 5 0.02), with statistical trends towards increased risk with increasing age (p 5 0.08) and atrial fibrillation (p 5 0.06) (figure 3). No difference in risk was observed for study center (table e-5), sex, degree of ipsilateral stenosis, or earlier TIA/stroke within 7 days before the presenting event.
In a model adjusting for age, sex, and study center, only age (adjusted HR for each 10-year age increase 1.6, CI 1.1-2.2; p 5 0.01) was associated with 90day stroke recurrence, with a trend observed for presentation with a cerebral event (stroke/TIA) (adjusted HR 2.7, CI 0.9-7.8; p 5 0.066). On backward stepwise Cox regression, after insertion and sequential removal of nonsignificant potential confounding variables, our results were unchanged (adjusted HR for each 10-year age increase 1.5, CI 1.1-2.2; p 5 0.02, adjusted HR for presentation with cerebral vs ocular event 2.7, CI 0.95-7.3; p 5 0.064) (table e-6). DISCUSSION The main finding of our study is the quantification of the risk of ipsilateral stroke and other ischemic events during early time intervals after initial symptom onset in pooled recent cohort studies of patients with carotid stenosis with high rates of treatment with modern stroke prevention medications. Our relatively large sample size provides greater precision around the point estimates of stroke risk at each time interval compared with earlier studies. We found high risk of recurrent events within the first days after first symptomatic medical presentation. At 3 days, the risk of recurrent stroke was 6.6% and that of any ischemic cerebral or ocular event was 14.6%. Within the first 14 days (the currently recommended time interval for CEA), the risk of recurrent stroke was 11.5% and that of any ischemic recurrent event was almost 24%. By 90 days, these risks had near doubled to almost 20% and 40%, respectively. These recurrent events had significant impact upon individual patients, with one-third of recurrent strokes resulting in death or disability on follow-up assessment.
Other observational studies have reported high risk (4.0%-17.2%) of early stroke recurrence after TIA and ischemic stroke, with highest risk described in population-based studies with in-person followup. [6] [7] [8] [9] [10] 14 In rigorous population-based studies, we and others have also reported greater early recurrent stroke risk in patients with TIA and stroke caused by carotid stenosis compared with cardioembolic, small vessel, or other stroke mechanisms. 7, 15 However, earlier reports have either included unselected patients with all stroke mechanisms or unselected patients with carotid stenosis/occlusion, many of whom are unsuitable for CEA/CAS due to disabling stroke or medical comorbidity. 7, 10 By contrast, in our pooled analysis, we analyzed early recurrence risk only in patients with recently symptomatic carotid stenosis deemed eligible for carotid revascularization, which is of proven benefit in randomized clinical trials. 1 Imaging studies using transcranial Doppler ultrasound 16 and PET 17 suggest that early recurrent ischemic events are related to frequent platelet-rich emboli associated with unstable inflammatory or ulcerated carotid plaque, or to impaired cerebral hemodynamic reserve in patients with nearocclusive carotid atherosclerosis. 18 After adjusting for other variables, we found that greater age was independently associated with early recurrent stroke, with a strong statistical trend for the association between stroke risk and presentation with an initial cerebral rather than ocular ischemic event. In pooled analysis of aspirin-treated patients in the medical arms of randomized trials, the Carotid Endarterectomy Trialists Collaboration found that 5year ipsilateral stroke risk increased in a linear fashion with age and was approximately doubled in patients whose initial (qualifying) event was a cerebral infarct compared to ocular ischemia. 1 We found no relationship between sex and early recurrent stroke risk, unlike medically treated patients in randomized trials, where a strong trend towards greater late stroke risk in men was observed. 19 We also found a statistical trend for the association between atrial fibrillation and Risk of ipsilateral stroke/retinal artery occlusion (RAO) within 2, 7, 14, and 90 days
The risk of ipsilateral ischemic stroke or RAO within 2, 7, 14, and 90 days after the presenting event in subgroups. Data derived from Kaplan-Meier analysis using carotid endarterectomy (CEA)/carotid artery stenting (CAS) as censor. Error bars denote 95% confidence interval. The p values are derived by logrank tests. AP/AC-med 5 antiplatelet or anticoagulant medication; At 2 days (for medication) 5 use of medication at 2 days after seeking medical attention; BP med 5 blood pressure-reducing medication; event within 7 days before 5 ipsilateral ischemic event within 7 days before the presenting event; hypertension 5 blood pressure .140/90 mm Hg or use of blood pressure-lowering medication.
stroke risk, suggesting a role for early stroke prophylaxis in patients with atrial fibrillation and ipsilateral carotid stenosis. On adjusted analyses, we did not observe relationships between diabetes, smoking, vascular risk factors, or other medication and early recurrence. Overall, our findings are consistent with those for late stroke outcome in earlier randomized trials, despite high rates of immediate antiplatelet and statin treatment in our study. This similarity also extends to the severity of the recurrent events. 14 Strengths of our analysis include a relatively large sample of patients treated with current medical therapy, prospective design of included studies, standardized hard primary outcome definitions (recurrent stroke rather than symptom progression or TIA), and inclusion only of patients eligible for CEA/CAS. However, we acknowledge some limitations. As the data were derived from independent studies performed at 3 centers, a predefined multicenter protocol was not used, and data were not available for all potentially informative variables (e.g., patients with high intensity statin treatment, intracranial stenosis). Categorization of patients with severe stenosis according to the degree of distal lumen diameter reduction was not standardized across centers. 20 Therefore, patients with near occlusion were included with those with severe stenosis in our study. Assessment of carotid stenosis was based on the opinion of the treating radiologist at each center using different imaging techniques and not centrally assessed. Treatment administered does not represent optimal medical therapy since one third of patients did not receive early statin treatment.
Although key clinical and treatment parameters were captured, we cannot exclude the possibility that international differences in health systems or referral patterns may have introduced undetected between-center variation. While larger than earlier studies, we may have lacked statistical power for the detection of modest associations between candidate predictor variables and recurrent stroke.
Our findings further support the hypothesis that urgent intensive treatment may decrease stroke risk in patients with symptomatic carotid stenosis. In clinical trials, maximal benefit was observed in patients who underwent CEA within 14 days of randomization. 1, 19 Although most guidelines currently recommend CEA within 2 weeks of symptom onset, this goal is frequently not met in routine practice. 10, 21, 22 In our study, despite patients deemed suitable for CEA, the rate of revascularization within 14 days varied from 16% to 54% across centers.
As our studies included patients treated in the years shortly after updates of guidelines to recommend early CEA in symptomatic patients, it is possible that these differing rates may be partly explained by variation in early implementation of new guidelines across study centers. Other studies from North America and Europe have reported similar low rates of early CEA in symptomatic patients. 21, 22 Some recent guidelines and experts have recommended CEA within 48 hours of initial symptoms, informed by post hoc analyses from randomized trials suggesting that urgent surgery might provide net benefit despite increased perioperative risk. 23,24 However, the net benefit of urgent surgery remains unclear as newer antiplatelet agents and statins were unavailable in the medical comparison arms of earlier trials and high rates of perioperative stroke and death have been reported with urgent CEA. 1,4,5 For example, a large Swedish registry reported a stroke/death rate of 11.5% in patients who had CEA within 2 days, while a systematic review reported stroke/death rates of 11.4% for patients who had emergency CEA for crescendo TIA and 20.2% for stroke-in-evolution. 4, 25 Improvements in urgent medical therapy since earlier randomized trials may also provide benefit. A recent population-based study reported a 10-fold decrease in recurrent ischemic events, with no recurrent strokes, in patients awaiting CEA after introduction of urgent high-dose dual clopidogrel/aspirin and statin therapy, consistent with findings from the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis study and Clopidogrel in High-Risk Patients with Acute Nondisabling Cerebrovascular Events trial. [26] [27] [28] As with our study, we caution that many of these studies were nonrandomized and that undetected bias that might partly explain their results cannot be fully excluded. Randomized clinical trials comparing current medical treatment to early CEA/CAS in moderate risk patients are underway. 29 Further randomized trials in symptomatic patients comparing urgent medical treatment, urgent CEA within 48-72 hours, and early CEA in the 3-14 day time window are required.
AUTHOR CONTRIBUTIONS
Elias Johansson: wrote the first draft of the manuscript, performed the statistical analyses, initiated and codesigned the current pooled analysis, designed and gathered most data in the Umeå center substudy. Elisa Cuadrado-Godia: codesigned the current pooled analysis, gathered all data in the Barcelona center substudy, assembled the pooled database, and contributed to manuscript review. Derek Hayden: data collection, data management, reviewed and contributed to the manuscript. Jakob Bjellerup: gathered data in the Umeå center substudy and contributed to manuscript preparation. Angel Ois: contributed to study design and manuscript review. Jaume Roquer: supervised the database from the Barcelona center and helped in manuscript review. Per Wester: made constructive remarks on the manuscript, codesigned and supervised the Umeå center substudy. Peter J. Kelly: designed, raised funding for, and supervised the Dublin TIA and population studies, codesigned pooled analysis, data collection, data management, data analysis, reviewed and wrote the manuscript with Dr. Johansson.
STUDY FUNDING
Supported by the Swedish Heart and Lung Foundation, the Swedish Stroke Foundation, the Northern Swedish Stroke Fund, the County of Västerbotten, the medical faculty of Umeå University, Spain's Ministry
